Application note: Generating clonal GFP cell lines
Namocell single cell dispensers use gentle sorting pressure to isolate and dispense GFP-positive cells into 96-well plates.
List view / Grid view
Namocell single cell dispensers use gentle sorting pressure to isolate and dispense GFP-positive cells into 96-well plates.
A selective FACS-enrichment was performed via the enrichment mode of Namocell Single Cell Dispenser to enrich for high titer CHO cells.
Watch Dr David Rimm from the Yale School of Medicine talk about his recent work and take on the future of multiplex spatial profiling of the TME.
Proteomic platform developed by US scientists affords a greater insight into the dynamics of iron-sulphur clusters delivery and binding.
Explore pathways of cell cycle control, revealing mechanisms of cell cycle arrest, DNA damage and senescence using this ebook.
Japanese researchers combine cutting edge mass spectrometry with software analysis to elucidate mRNA structure.
Oestrogen receptors play a crucial role in breast cancer. By making them therapeutic targets, oestrogen can be regulated with the aim to prevent breast cancer.
US researchers uncover the amino acid: arginine, that prompts genetic mutations in cancer cells.
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
US researchers revealed that MRSA has undergone repeated mutations in the sarZ gene, leading to increased severity of blood stream infections in mouse models.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
The scientists say that the engineered CRISPR enzymes could overcome key limitations for eventual use to treat genetic diseases irrespective of a patient’s particular mutation.
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.